Suppr超能文献

氯离子自由与限制的静脉输液治疗与急性肾损伤:一项扩展分析。

Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis.

机构信息

Austin Health, Heidelberg, Australia.

出版信息

Intensive Care Med. 2015 Feb;41(2):257-64. doi: 10.1007/s00134-014-3593-0. Epub 2014 Dec 18.

Abstract

PURPOSE

In a previous study, restricting intravenous chloride administration in ICU patients decreased the incidence of acute kidney injury (AKI). To test the robustness of this finding, we extended our observation period to 12 months.

METHODS

The study extension included a 1-year control period (18 August 2007 to 17 August 2008) and a 1-year intervention period (18 February 2009 to 17 February 2010). During the extended control period, patients received standard intravenous fluids. During the extended intervention period, we continued to restrict all chloride-rich fluids. We used the Kidney Disease: Improving Global Outcomes (KDIGO) staging to define AKI.

RESULTS

We studied 1,476 control and 1,518 intervention patients. Stages 2 and 3 of KDIGO defined AKI decreased from 302 (20.5 %; 95 % CI, 18.5-22.6 %) to 238 (15.7 %; 95 % CI, 13.9-17.6 %) (P < 0.001) and the use of RRT from 144 (9.8 %; 95 % CI, 8.3-11.4 %) to 103 (6.8 %; 95 % CI, 5.6-8.2 %) (P = 0.003). After adjustment for relevant covariates, liberal chloride therapy remained associated with a greater risk of KDIGO stages 2 and 3 [hazard ratio 1.32 (95 % CI 1.11-1.58); P = 0.002] and use of RRT [hazard ratio 1.44 (95 % CI 1.10-1.88); P = 0.006]. However, on sensitivity assessment of each 6-month period, KDIGO stages 2 and 3 increased in the new extended intervention period compared with the original intervention period.

CONCLUSIONS

On extended assessment, the overall impact of restricting chloride-rich fluids on AKI remained. However, sensitivity analysis suggested that other unidentified confounders may have also contributed to fluctuations in the incidence of AKI.

摘要

目的

在之前的研究中,限制 ICU 患者静脉内氯的摄入可降低急性肾损伤(AKI)的发生率。为了验证这一发现的稳健性,我们将观察期延长至 12 个月。

方法

研究扩展包括 1 年的对照期(2007 年 8 月 18 日至 2008 年 8 月 17 日)和 1 年的干预期(2009 年 2 月 18 日至 2010 年 2 月 17 日)。在延长的对照期内,患者接受标准静脉输液。在延长的干预期内,我们继续限制所有富含氯的液体。我们使用肾脏病:改善全球预后(KDIGO)分期来定义 AKI。

结果

我们研究了 1476 例对照患者和 1518 例干预患者。KDIGO 分期 2 和 3 的 AKI 从 302 例(20.5%;95%CI,18.5-22.6%)降至 238 例(15.7%;95%CI,13.9-17.6%)(P<0.001),接受 RRT 的比例从 144 例(9.8%;95%CI,8.3-11.4%)降至 103 例(6.8%;95%CI,5.6-8.2%)(P=0.003)。在调整了相关协变量后,自由氯治疗与 KDIGO 分期 2 和 3 的风险增加相关[危险比 1.32(95%CI 1.11-1.58);P=0.002]和 RRT 的使用[危险比 1.44(95%CI 1.10-1.88);P=0.006]。然而,在对每个 6 个月的时间段进行敏感性评估后,新的延长干预期与原始干预期相比,KDIGO 分期 2 和 3 的发生率增加。

结论

在扩展评估中,限制富含氯的液体对 AKI 的总体影响仍然存在。然而,敏感性分析表明,其他未识别的混杂因素也可能导致 AKI 发生率的波动。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验